Business interests lobby the US government to bully developing countries into changing their economic laws and practices so as to favor the commercial interests of multinationals. Unfortunately this can come at the expense of health, education and other sensitive public interests. We are countering the corporations’ analysis and arguing for a more independent US government policymaking that defends global health.
For example, I testified at a recent hearing by the US Trade Representative, criticizing the US Government’s Special 301 “Watch List.” At stake is India’s key role helping facilitate global access to affordable medicines. Read more here.
works with partners worldwide to improve health outcomes and save lives, through use of pharmaceutical cost-lowering measures including generic competition. We help civil society groups and public agencies overcome patent-based and other drug monopolies. We assess new developments in policy and law, and work with coalition partners to promote game-changing ideas that advance pharmaceutical access and innovation simultaneously. Read more.